Why the study?
Does linagliptin alone or combined with telmisartan reduce diabetic nephropathy progression in diabetic eNOS knockout mice?
Does linagliptin alone or combined with telmisartan reduce diabetic nephropathy progression in diabetic eNOS knockout mice?
DPP-4 inhibition with linagliptin on top of ARB therapy significantly reduces albuminuria and oxidative stress in a mouse model of diabetic nephropathy.
Authors
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for additive renoprotection with linagliptin on ARB background; does not support clinical use without human trials.
Alter et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: